跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,787 条关于
“Yuhan Corporation”
全部
1,787
临床试验
151
药物
194
机构
482
资讯
960
2个月前
Yuhan Corporation Presents Phase 1b Results for Novel Anti-IgE Allergy Drug Lesigercept at EAACI 2026
去年
Yuhan Corporation Receives $15 Million Milestone from Janssen Following Japan Launch of Lazertinib-Amivantamab Combination for EGFR-Mutated NSCLC
2年前
Leclaza Monotherapy Shows Promise in EGFR-Mutated NSCLC
2年前
FDA Approves Lazertinib Plus Amivantamab for First-Line EGFR-Mutated NSCLC
去年
Yuhan's Lung Cancer Drug Leclaza Secures European Approval in Combination Therapy
5个月前
Yuhan's YH35995 Receives FDA Orphan Drug Designation for Gaucher Disease Treatment
去年
Immuneoncia Therapeutics Raises $24M in Successful Kosdaq IPO for Cancer Drug Development
去年
Yuhan's Leclaza Secures FDA Approval for NSCLC Treatment, Marking Historic Entry into US Market
去年
Urticaria Clinical Trial Pipeline Heats Up with Novel Therapies in Development
去年
EC Approves Amivantamab Plus Lazertinib for First-Line EGFR-Mutated NSCLC
第 1 页,共 96 页
上一页
下一页